AnteoTech (ADO) AGM 2025 summary

Opening remarks and agenda

• Chair opened the meeting, acknowledged traditional custodians, and outlined meeting protocols and safety procedures.

• Introduced board members, executive team, and external auditor; confirmed notice of meeting and minutes of previous AGM were tabled.

• Outlined meeting structure, voting procedures, and eligibility for questions and voting.

• Welcome and overview presented, with a focus on products, technology, plans, progress, and a Q&A session.

Board and executive committee updates

• Chair highlighted her recent appointment and focus on commercial strategy, governance, and repositioning for near-term opportunities.

• CEO appointment made permanent after successful organizational restructuring and culture shift.

• Board remains intentionally small but may expand as needed for growth.

• New leadership team with commercial and technical expertise appointed to drive growth.

Financial performance review

• Life sciences revenue increased by 110% in FY 2025 compared to FY 2024, driven by new products and expanded customer base.

• Total revenue reached AUD 1 million, with a successful AUD 4.3 million capital raise and AUD 2.6 million R&D tax incentive supporting growth.

• Achieved AUD 1.6 million in annualised cost savings through restructuring and efficiency improvements.

• Secured AUD 6 million in federal and state grant funding, including a retained AUD 4 million ARENA grant with milestone extension into 2026.